Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Pediatrics

Long-Term Monitoring and Life After Diagnosis

At a Glance

After diagnosis, children with hyperinsulinism-hyperammonemia syndrome need ongoing developmental screening, seizure evaluation, and diazoxide safety checks. Early therapy and school support can address concerns promptly, and caregiver mental health is an essential part of long-term care.

While stable blood sugar is the primary goal of treatment, the “long-term” journey with HI/HA syndrome involves much more than just managing numbers. Because the brain requires a constant, steady supply of fuel to grow, the period before your child was diagnosed—and even the time since—can have a lasting impact on their development [1][2]. Proactive monitoring is the best tool you have to ensure your child reaches their full potential.

Understanding Neurodevelopmental Risks

Research shows that many children with HI/HA face challenges that persist even after their blood sugar is well-controlled with medication [3][4]. In some specific cohorts of patients, 64% to 73% of evaluated children experienced some form of neurodevelopmental issue [4].

  • Common Challenges: These often include speech delays, learning disabilities, and difficulties with fine motor skills or attention [5][6].
  • The Cause: These issues are often linked to hypoglycemic brain injury that occurred before the diagnosis was made, particularly if the child experienced very low blood sugar levels or severe seizures early in life [7][1]. It is important to know that these statistics come from specific studies and are not a deterministic prediction for your child. Duration, recurrence, age, and individual resilience all matter.
  • The Role of GLUD1: Some researchers are also investigating whether the GLUD1 mutation itself affects the brain’s chemical balance (glutamate), which might contribute to these challenges independently of blood sugar [8].

Epilepsy and Seizure Monitoring

Even with good blood sugar control, epilepsy remains a significant concern, affecting approximately 29% to 36% of children in evaluated HI/HA cohorts [4][5]. It is important to know that while many seizures in this condition are “hypoglycemic” (caused by low sugar), some children develop seizures that happen even when their blood sugar is normal [9][8]. If your child continues to have “spells” or staring episodes despite stable sugar readings, a referral to a pediatric neurologist for an EEG (a test of the brain’s electrical activity) is essential [5][8].

A Lifetime Surveillance Plan

Managing HI/HA is a marathon, not a sprint. Experts recommend a consistent schedule of “check-ups” for the whole child, not just their pancreas:

  • Routine Developmental Screening: Frequent screenings for language, motor, and social milestones should occur during regular pediatric visits [10].
  • Early-Intervention Referral: If any concern appears, ask for a referral to physical, occupational, or speech therapy immediately.
  • Neuropsychological Assessment: As your child approaches school age, formal testing can identify specific needs in memory, attention, or visual processing, with reassessments during major school transitions [6].
  • Cardiac Screening: For children taking diazoxide, a baseline and early follow-up echocardiogram (heart ultrasound) are typically recommended to monitor for a rare but serious side effect called pulmonary hypertension. Ongoing monitoring should be individualized based on age, risk, symptoms, and local guidance [11][12]. Note: Urgent breathing or circulation symptoms should never wait for a scheduled scan.
  • Blood Work: Regular tests for white blood cell counts (neutropenia) and uric acid are standard for those on long-term diazoxide therapy [12].

The Psychological Toll on Caregivers

It is completely normal to feel a high level of hyper-vigilance—a state of constant alertness—when caring for a child with HI/HA [13][14]. The fear of a “hidden low,” especially overnight, leads many parents to check monitors multiple times an hour [14].

Studies have found that nearly 40% of parents of children with persistent hyperinsulinism screen positive for anxiety, and many experience significant sleep disruption [13]. Taking care of your own mental health is not a luxury; it is a vital part of your child’s care team. Seeking out peer support groups, such as those through Congenital Hyperinsulinism International, can provide practical advice and emotional relief from those who truly understand the journey [15][16].

Looking Ahead

The prognosis for HI/HA varies widely. While some children face significant hurdles, others grow up with normal intelligence and lead typical lives [17][18]. The key is early intervention—identifying a speech delay or a learning gap as soon as it appears so that support systems, like physical therapy or school-based accommodations, can be put in place immediately [10][15].

Common questions in this guide

What long-term developmental checks does a child with HI/HA syndrome need?
Regular pediatric visits should include screening of language, movement, learning, and social development. If concerns arise, early referral to speech, occupational, or physical therapy can provide support, and formal testing of memory, attention, and learning can be useful near school age and during major school transitions.
Can a child with HI/HA have seizures when blood sugar is normal?
Yes. Some children have seizures unrelated to low blood sugar, including staring or other unusual spells that continue despite stable readings. A pediatric neurologist may recommend an EEG, which records the brain's electrical activity, to evaluate these events.
What tests are needed if my child takes diazoxide long term?
Children taking diazoxide typically have a baseline and early follow-up echocardiogram, an ultrasound of the heart, to check for pulmonary hypertension. Doctors also monitor white blood cell counts for neutropenia, or low levels of infection-fighting cells, and uric acid. The schedule depends on the child's age, symptoms, risks, and clinical guidance; breathing or circulation symptoms need urgent attention.
Does good blood sugar control eliminate the risk of developmental problems?
Not always. Developmental difficulties can reflect low blood sugar or severe seizures that occurred before diagnosis, and researchers are also studying whether changes in the GLUD1 gene may affect brain chemistry. These findings describe risk in groups and cannot predict a specific child's outcome, so ongoing screening and early support remain important.
How can caregivers cope with constant worry about low blood sugar?
Fear of an unnoticed low can cause constant alertness, repeated overnight checks, anxiety, and sleep loss. Sharing monitoring with a trusted secondary caregiver, taking regular breaks, connecting with peer groups, and seeking mental-health support can help protect caregiver well-being.
What is the long-term outlook for children with HI/HA syndrome?
The outlook varies widely. Some children develop significant learning, attention, motor, or seizure-related challenges, while others have typical intelligence and lives. Finding concerns early and using therapy or school accommodations can help each child reach their potential.

Get notified when new evidence is published on Hyperinsulinism-hyperammonemia syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    Risk Factors for Adverse Neurodevelopment in Transient or Persistent Congenital Hyperinsulinism.

    Roeper M, Salimi Dafsari R, Hoermann H, et al.

    Frontiers in endocrinology 2020; (11()):580642 doi:10.3389/fendo.2020.580642.

    PMID: 33424766
  2. 2

    Both Low Blood Glucose and Insufficient Treatment Confer Risk of Neurodevelopmental Impairment in Congenital Hyperinsulinism: A Multinational Cohort Study.

    Helleskov A, Melikyan M, Globa E, et al.

    Frontiers in endocrinology 2017; (8()):156 doi:10.3389/fendo.2017.00156.

    PMID: 28740482
  3. 3

    Hyperinsulinism hyperammonaemia (HI/HA) syndrome due to GLUD1 mutation: phenotypic variations ranging from late presentation to spontaneous resolution.

    Brandt A, Agarwal N, Giri D, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2020; (33(5)):675-679.

    PMID: 32229669
  4. 4

    Natural History of the Hyperinsulinism/Hyperammonemia Syndrome: A Retrospective Review Incorporating Patient-Centered Data.

    Rosenfeld E, Taylor O, Mitteer LM, et al.

    Hormone research in paediatrics 2026; 1-11 doi:10.1159/000551535.

    PMID: 41980002
  5. 5

    Spectrum of neuro-developmental disorders in children with congenital hyperinsulinism due to activating mutations in GLUD1.

    Aftab S, Gubaeva D, Houghton JAL, et al.

    Endocrine connections 2023; (12(4)).

    PMID: 35951311
  6. 6

    The effect of hypoglycaemia on neurocognitive outcome in children and adolescents with transient or persistent congenital hyperinsulinism.

    Muukkonen L, Männistö J, Jääskeläinen J, et al.

    Developmental medicine and child neurology 2019; (61(4)):451-457 doi:10.1111/dmcn.14039.

    PMID: 30246438
  7. 7

    A novel mutation in the glutamate dehydrogenase (GLUD1) of a patient with congenital hyperinsulinism-hyperammonemia (HI/HA).

    Fang C, Ding X, Huang Y, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2016; (29(3)):385-8.

    PMID: 26656609
  8. 8

    Characterizing the neurological phenotype of the hyperinsulinism hyperammonemia syndrome.

    Rosenfeld E, Nanga RPR, Lucas A, et al.

    Orphanet journal of rare diseases 2022; (17(1)):248 doi:10.1186/s13023-022-02398-3.

    PMID: 35752848
  9. 9

    Hyperinsulinism-hyperammonemia syndrome: a de novo mutation of the GLUD1 gene in twins and a review of the literature.

    Ninković D, Sarnavka V, Bašnec A, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2016; (29(9)):1083-8.

    PMID: 27383869
  10. 10

    Real-world insights into neurodevelopmental outcomes amongst people with congenital hyperinsulinism.

    Lopez LN, Banerjee I, De Leon DD, et al.

    Orphanet journal of rare diseases 2026; (21(1)).

    PMID: 42399951
  11. 11

    Pericardial Effusion Associated with Diazoxide Treatment for Congenital Hyperinsulinism.

    Hastings LA, Preddy J, McCready M, et al.

    Hormone research in paediatrics 2020; (93(3)):206-211 doi:10.1159/000507624.

    PMID: 32580193
  12. 12

    Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide.

    Herrera A, Vajravelu ME, Givler S, et al.

    The Journal of clinical endocrinology and metabolism 2018; (103(12)):4365-4372 doi:10.1210/jc.2018-01613.

    PMID: 30247666
  13. 13

    Anxiety, depression, and quality of life in parents of children with congenital hyperinsulinism.

    Roeper M, Hoermann H, Salimi Dafsari R, et al.

    European journal of pediatrics 2022; (181(7)):2779-2788 doi:10.1007/s00431-022-04486-9.

    PMID: 35507217
  14. 14

    Continuous Glucose Monitoring in the Management of Congenital Hyperinsulinism: A National User-satisfaction Survey, UK.

    Couch H, Pearson A, Malhotra N, et al.

    The Journal of clinical endocrinology and metabolism 2025; (111(1)):139-148 doi:10.1210/clinem/dgaf313.

    PMID: 40418653
  15. 15

    Congenital Hyperinsulinism International: A Community Focused on Improving the Lives of People Living With Congenital Hyperinsulinism.

    Raskin J, Pasquini TLS, Bose S, et al.

    Frontiers in endocrinology 2022; (13()):886552 doi:10.3389/fendo.2022.886552.

    PMID: 35573986
  16. 16

    Parent experiences of infant feeding in congenital hyperinsulinism: a thematic analysis.

    Worthington S, Ginbey E, Otabor O, et al.

    Frontiers in endocrinology 2026; (17()):1955679 doi:10.3389/fendo.2026.1955679.

    PMID: 42978621
  17. 17

    Clinical and Molecular Spectrum of Glutamate Dehydrogenase Gene Defects in 26 Chinese Congenital Hyperinsulinemia Patients.

    Su C, Liang XJ, Li WJ, et al.

    Journal of diabetes research 2018; (2018()):2802540 doi:10.1155/2018/2802540.

    PMID: 30306091
  18. 18

    Hyperinsulinism-hyperammonemia Syndrome in an Infant with Seizures.

    Strajnar A, Tansek MZ, Podkrajsek KT, et al.

    Balkan journal of medical genetics : BJMG 2018; (21(1)):77-81 doi:10.2478/bjmg-2018-0014.

    PMID: 30425915

This page is for informational purposes only and does not constitute medical advice. Your child's pediatric, neurology, developmental, and mental-health care teams should tailor monitoring and support to your child's needs.